AMAG Pharma Sees Q4 Revenue Above Consensus

(RTTNews) - AMAG Pharmaceuticals, Inc. (AMAG) said Monday that it expects fourth quarter total revenues to be in the range of $21.3 to $21.8 million, including between $18.6 and $19.1 million of U.S. Feraheme net product revenues.

The company also said it now expects 2013 total annual revenues of $80.5 million to $81.0 million, compared to its prior guidance of $78 million to $81 million.

Analysts polled by Thomson Reuters currently expect the company to post revenue of $21.12 million for the fourth quarter and $80.59 million for the full year 2013.

"We achieved or exceeded each financial objective that we set for our business at the beginning of 2013," said Frank Thomas, executive vice president and chief operating officer of AMAG. "This puts us in a strong position as we pursue our 2014 goals of building AMAG's product portfolio and growing the base of business that we have established with Feraheme."